China Pharma Holdings (CPHI) Non Operating Interest Expenses (2010 - 2026)

China Pharma Holdings (CPHI) has reported Non Operating Interest Expenses for 17 consecutive years, with $26359.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 3.66% year-over-year to $26359.0; the trailing twelve-month figure through Jun 2026 stood at $66067.0 (down 4.3% YoY), and the FY2025 full-year result was $27272.0, changed 0.3% from the prior year.
• Non Operating Interest Expenses improved to $26359.0 in Q2 2026 per CPHI's latest filing, from $26031.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $137663.0 in Q2 2023 and bottomed at -$252776.0 in Q4 2023.
• Historically, Non Operating Interest Expenses has averaged $34111.0 across 5 years, with a median of $26859.0 in 2025.
• The sharpest annual moves came in 2023 and 2025: Non Operating Interest Expenses sank 362.83% in 2023, then surged 308.81% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $96175.0 in 2022, then plunged by 362.83% to -$252776.0 in 2023, then jumped by 102.69% to $6802.0 in 2024, then increased by 1.13% to $6879.0 in 2025, then jumped by 283.18% to $26359.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $26359.0, $26031.0, and $6879.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.